Cargando…

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism

CONTEXT: Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. OBJECTIVE: This work aimed to investigate the safety, tolerability, and efficacy of daily Tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Aliya A, Rejnmark, Lars, Rubin, Mishaela, Schwarz, Peter, Vokes, Tamara, Clarke, Bart, Ahmed, Intekhab, Hofbauer, Lorenz, Marcocci, Claudio, Pagotto, Uberto, Palermo, Andrea, Eriksen, Erik, Brod, Meryl, Markova, Denka, Smith, Alden, Pihl, Susanne, Mourya, Sanchita, Karpf, David B, Shu, Aimee D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684498/ https://www.ncbi.nlm.nih.gov/pubmed/34347093 http://dx.doi.org/10.1210/clinem/dgab577

Ejemplares similares

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults
por: Karpf, David B, et al.
Publicado: (2020)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
por: Clarke, Bart, et al.
Publicado: (2023)

Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES)
por: Brod, Meryl, et al.
Publicado: (2021)

Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact)
por: Brod, Meryl, et al.
Publicado: (2020)

Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom)
por: Brod, Meryl, et al.
Publicado: (2019)

MON-LB092 Understanding the Patient-Centered Impact of Hypoparathyroidism on Functioning and Well-Being
por: Brod, Meryl, et al.
Publicado: (2019)

Disease Burden of Patients Living With Hypoparathyroidism: Results From the Voices of Hypopara Survey
por: Murphy, Deborah, et al.
Publicado: (2021)

The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics
por: Gittoes, Neil, et al.
Publicado: (2021)

OR29-5 Phase 3 PaTHway Trial: Participants Treated With TransCon PTH Achieved Independence From Conventional Therapy While Maintaining Normal Serum Calcium
por: Khan, Aliya
Publicado: (2022)

Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84)
por: Chen, Kristina S, et al.
Publicado: (2020)

The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency
por: Sprogøe, Kennett, et al.
Publicado: (2017)

Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study
por: Marcucci, Gemma, et al.
Publicado: (2021)

Recent advances in understanding and managing hypoparathyroidism
por: Rubin, Mishaela R.
Publicado: (2020)

Serum Calcium Levels in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Rejnmark, Lars, et al.
Publicado: (2021)

Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1–84): A Retrospective Cohort Study
por: Ayodele, Olulade, et al.
Publicado: (2022)

Continuous rhPTH (1–34) treatment in chronic hypoparathyroidism
por: Fuss, Carmina Teresa, et al.
Publicado: (2020)

SAT-399 Baseline Characteristics from the Observational PARADIGHM Registry of Patients with Chronic Hypoparathyroidism
por: Clarke, Bart L, et al.
Publicado: (2020)

Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment
por: Marcucci, G., et al.
Publicado: (2022)

Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Gosmanova, Elvira, et al.
Publicado: (2021)

Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
por: Ayodele, Olulade, et al.
Publicado: (2022)

Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus
por: Khan, Aliya A, et al.
Publicado: (2018)

Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
por: Clarke, Bart L., et al.
Publicado: (2016)

Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
por: Brod, Meryl, et al.
Publicado: (2023)

Low health-related quality of life in hypoparathyroidism and need for PTH analog
por: Kontogeorgos, Georgios, et al.
Publicado: (2021)

The Role of the Patient Partnership in Designing Research on Neuropsychiatric Issues in Hypoparathyroidism
por: Rubin, Mishaela R
Publicado: (2023)

OP Transcon 2018 Compilation
Publicado: (2019)

PP Transcon 2018 Compilation
Publicado: (2019)

Hypoparathyroidism: Replacement Therapy with Parathyroid Hormone
por: Rejnmark, Lars, et al.
Publicado: (2015)

Therapy of Hypoparathyroidism by Replacement with Parathyroid Hormone
por: Rejnmark, Lars, et al.
Publicado: (2014)

Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation
por: Liao, E Pauline, et al.
Publicado: (2023)

TRANSCON 2022 B: Poster Papers
Publicado: (2023)

TRANSCON 2022 B: Oral Abstracts
Publicado: (2023)

SAT-396 A Non-Surgical Animal Model of Hypoparathyroidism for Testing PTH Analogues
por: Ramezani-Pour, Narjes, et al.
Publicado: (2020)

Total thyroidectomy: reduction in postoperative hypoparathyroidism
por: Reinke, Rasmus, et al.
Publicado: (2023)

OR07-03 Continuous Subcutaneous Delivery of RhPTH(1-84) by Pump in Adults with Hypoparathyroidism
por: Bove-Fenderson, Erin, et al.
Publicado: (2020)

Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: Renal disease in chronic hypoparathyroidism
por: Gosmanova, Elvira O., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cod29e1222tn2kcoi4k8sj0tvj